The occurrence and severity of erythroblastosis fetalis, due to maternal Rh isoimmunization, can be predicted through simple prenatal serological tests (1, 2) . If Rh isoagglutinins are present in maternal serum, and if the incompatible Rh antigen is transmitted from the father, the newborn will have hemolytic disease, the severity of which is often proportional to the titer of the mother's serum Rh isoagglutinins (1, 2) . In the event that the isoimmunized Rh negative mother delivers an Rh negative infant, the titer of Rh antibodies in the cord serum, except for saline agglutinins, is generally equal to the titer obtained in the maternal serum (3) . For practical purposes, almost all maternal Rh isoagglutinins seem to cross the placental barrier freely, and their titration value affords guidance toward the effective management of hemolytic disease of the newborn. This has not been the case for erythroblastosis fetalis due to ABO incompatibility (1, 2) .
ABO erythroblastosis of sufficient severity to warrant exchange transfusion therapy for the control of hyperbilirubinemia, has a frequency equal to that of erythroblastosis due to Rh incompatibility (2, 4) , and yet prenatal tests have been of little value thus far in identifying those mothers who may deliver affected infants (4) . Since ABO erythroblastosis occurs often in the first incompatible pregnancy (5, 6) , a reliable prenatal test would be of extreme importance in anticipating the occurrence of this disease for intelligent management. A varying proportion of maternal anti-A (a) and anti-B (,/) isoagglutinins can be demonstrated in the serum of the newborn (7, 8) . Most ABO isoagglutinins cannot cross the placenta and therefore play no role in the pathogenesis of erythroblastosis. Fudenberg, Kunkel and Franklin (9) suggested that 7S isoagglutinins traverse the placental barrier, thus predisposing to hemolytic disease. If so, diffusion of antibodies across the placenta may be dependent upon the molecular size of the antibody molecule, with low molecular weight (about 160,000) Y2 antibodies of the mother reaching the fetus (9) .
Of equal importance in the pathogenesis of ABO hemolytic disease of the newborn are the protective effects of nonerythrocytic ABO blood group substances in the fetus. Whereas Rh antigens appear to be restricted to the red blood cells, ABO antigens occur in other tissues, as well as in the secreted mucopolysaccharides of most persons (10) , and ABO isoagglutinins possess varying degrees of sensitivity to inhibition by specific soluble blood group substances (SSBGS) (11, 12 ). An excess of ABO secretors has been observed in infants with ABO erythroblastosis (5, 6, 13, 14) and in their fathers (14) . This excess may reflect either a sensitivity of ABO secretors, or a resistance of ABO nonsecretors, toward ABO disease, or even a loss of ABO nonsecretors in utero.
Since blood group substances are readily demonstrable in the tissues of both secretors and nonsecretors (15) , further quantitative and/or qualitative distinctions must exist between these two classes to explain these observations. Resistance to neutralization of some a and ,B isoagglutinins might be related to the clinical problem of ABO erythroblastosis, if such antibodies were 7S y2-globulins crossing the placenta (9) . Large antibody molecules (macroglobulins), because they fail to traverse the placental barrier, are not pertinent to this problem (9) .
Column chromatographic separation of serum proteins on anion exchanger, diethylaminoethyl (DEAE) cellulose, first described by Sober, Gutter, Wyckoff and Peterson (16, 17) , offers a relatively simple means of separating 7S /2-globulins from other serum proteins (18) . Such separation of human isoagglutinins has been reported by 874 Abelson and Rawson (19) and by Fahey and Morrison (20) .
The present report deals with the resistance to neutralization by SSBGS of ABO isoagglutinins which can traverse the placental barrier. These isoagglutinins were obtained by a simplified DEAE cellulose column chromatographic method, designed to separate 7S 7y-globulins from the remainder of the serum proteins. The results observed in the presence and the absence of ABO erythroblastosis suggest that the disease might be anticipated by suitable prenatal tests.
MATERIALS AND METHODS
Chromatographic separation was performed according to a modified method of Sober and Peterson (17) and of Levy and Sober (18) . In general, the following procedure was used for separation of serum: DEAE cellulose 1 was purified according to Sober and co-workers (16) and the slurry, suspended in the initial buffer (0.02 M phosphate, pH 6.3), was poured into 5-ml serological pipets (25 X 0.5 cm). The ion exchanger was packed under water pressure of 40 to 50 cm and washed with the initial buffer overnight. The dead volume of such columns was about 2.5 ml.
The serum sample, dialyzed2 against 3 changes of the initial buffer in a 4°C cold room, was applied to the column, together with the slight precipitate formed during dialysis. For each separation, 1 ml serum (corrected for the increase of volume during dialysis) was applied to the column at room temperature, and washed with 10 ml of the initial buffer, followed by 10 ml of 1 M NaCl. Two-ml samples were collected at a flow rate of 6 to 8 ml per hour, at room temperature. The protein content of the separated fractions was measured by absorption at 280 mg in a Beckman DU spectrophotometer.
Under these conditions, the 0.02 M phosphate buffer (pH 6.3) fraction (hereafter referred to as 0.02 M fraction) contained the first four chromatographic peaks described by Humphrey and Porter (21) , and if isoagglutinins were present in this fraction, the highest titers were always found in those tubes which contained most protein. No difference was found in the elution pattern of the isoagglutinins when 0.01 M phosphate buffer was followed by 0.02 M buffer, or when more than 10 ml of buffer was used as first eluent (Figure 1 ). The 0.02 M fraction was not found to contain proteins other than y2-globulins when tested by paper electrophoresis and acrylamide electrophoresis (22 The second fraction eluted with 1 M NaCl (hereafter referred to as 1 M fraction) contained 19S macroglobulins and all other serum proteins, but paper and acrylamide electrophoresis failed to reveal y2-globulins. The isoagglutinin activity of this fraction could be split into two fractions using, after 0.02 M phosphate buffer, pH 6.3, first 0.1 M phosphate buffer, pH 6.3, followed by 1 M NaCl (Figure 1 ). The significance of this observation is under study.
The isotonicity of 0.02 M phosphate buffer fractions was restored by addition of 0.05 ml of 18 per cent NaCl per 1 ml of eluate, and of 1 M NaCl fractions by dilution with 5 vol of distilled water.
Native serum and pooled fractions, the latter concentrated to the original serum volume by dialysis at 4°C against 20 per cent polyvinylpyrrolidone (PVP), provided materials for titration of antibodies before and after separation. Parallel titrations showed a good recovery of the isoagglutinins ( Table I) .
The agglutination tests for a and fi isoagglutinins were done by conventional methods, usually in duplicate. Twofold serial dilutions of serum or fractions were mixed with equal volumes of 2 per cent washed red cells from type A1 and B donors. After incubation at 370 C for 1 hour and centrifugation, agglutination was recorded as the saline titer. An additional volume of 4 per cent acacia (5) was then added and the mixture reincubated for 15 minutes at 37°C, centrifuged, and 1 vol of saline added to abolish rouleaux. The agglutination then observed, usually by two observers, neither familiar with the clinical details, was recorded as the acacia titer. This concentration of acacia was chosen because it afforded results which agreed within one dilution of those observed with the y-antiglobulin test.
The neutralization tests for a and 8 isoagglutinins were performed by mixing serial dilutions of 0.02 M phosphate buffer fractions with suitable serial dilutions of SSBGS lose columns offered such an opportunity, and 110 prenatal specimens of type 0, A and B patients were fractionated. Table IV shows the distribution of the blood types of the newborn subsequently delivered, and (3. mine that concentration which just failed to inhibit visible agglutination. These results, correlated with the ABO type of the newborn, are summarized in Table VI . The horse B substance used for these tests inhibited anti-B much less effectively than the hog A substance inhibited anti-A. Five prenatal sera so studied for placenta-crossing antibodies were found to contain a and/or p agglutinins, neither of which could be neutralized by SSBGS at a concentration of 1: 10 for A and 4: 1 for B. Four of these patients delivered type O newborn, but one delivered a type B child which required exchange transfusion therapy for severe ABO erythroblastosis.
In 200 deliveries, approximately 90 type 0 mothers can be anticipated, and in the small series shown in Tables III, IV and V, 73 type 0 mothers were studied. Therefore, 0.8 case of ABO disease was expected (23) , and one case was encountered. Type 0 mothers have incompatible offspring of types A, and B in approximately 30 per cent of instances (the sum of the gene frequencies of Al and B), so that for every case of erythroblastosis, an additional two to three unselected type 0 women should have similar ABO isoagglutinins which are of no importance to newborn of types 0 and A2 (23) . In the present series, four such women were encountered. One of these patients happened to be primagravida, consistent with the fact that ABO disease may be observed in the first incompatible pregnancy. (6) . On the other hand, titer in reases have been noted post partum following the delivery of some ABO incompatible secretors (6) , presumably due to the SSBGS content of amniotic fluid. This raises the question as to whether SSBGS can incite noninhibitable isoaggluitinins that can be eluted in 0.02 M fractions.
For information on this problem, the sera of five unselected type 0 donors, who had been immunized with both A and B SSBGS for preparation of anti-AB reagents (high titer type 0 sera), were fractionated on DEAE cellulose columns. The SSBGS which had been used for the immunization of these donors were of the same source and manufacture as those employed in the Table VIII .
DISCUSSION
Severe ABO erythroblastosis is familial and often observed in the first ABO incompatible child (5, 6) . Although almost all subsequent incompatible infants are also affected, increasing severity of the disease is not seen regularly (12, 14) . Thus ABO disease resembles Rh erythroblastosis in its familial incidence, but differs by not reflecting so much evidence of specific maternal isoimmunization by the products of conception.
Schiff (12) (15) and exert a protective effect of considerable magnitude, as evidenced by the low frequency of erythroblastosis despite the common occurrence of diffusible isoagglutinins (6, 8) .
At least four components, with sedimentation constants of 7S, 19S, 28S, and 44S, have been found in the y-globulin fractions of normal human serum (24) , and recently Fahey and Morrison (20) showed that all of the ABO isoagglutinins have a sedimentation value of either 7S or 19S. The "non-y-globulin" isoagglutinins reported by Abelson and Rawson (19) appear to have been due to conditions of the separation (20) . Abelson and Rawson also reported that noninhibitable ABO isoagglutinins were almost all located in 7S fractions; but in all cases, and at the same concentration of SSBGS that they employed, we found only a small part of the total isoagglutinins to be noninhibitable and to occur in both the 0.02 M and the 1 M fractions if isoagglutinins were present at all in the former. Table III reveals that most ABO isoagglutinins are not y2-globulins and do not cross the placenta. Poorly inhibitable isoagglutinins eluted in 1 M fractions, although not shown in this report, were observed frequently and would contribute misleading information.
Placental permeability and resistance to inhibition by SSBGS are certainly not the sole parameters of the problem of ABO erythroblastosis, but their contribution must be of primary consideration. Other contributing factors include the expression of erythrocytic ABO antigens because A2 children tend to be spared (6) ; the secretor status because erythroblastotic infants tend to be secretors (5, 13, 6, 14) ; and the ability of the affected newborn to cope with a hemolytic syndrome (4). These and, probably, other variables must be studied. If the noninhibitable isoagglutinins of 0.02 M fractions are responsible for ABO erythroblastosis, there is now an opportunity to attack these secondary problems.
The present report raises an immediate problem concerning the nature of noninhibitable isoagglutinins shown to be associated with erythroblastosis. If these antibodies can be incited by SSBGS (Table VIII) , they should not represent antigenic structural grouping differences between erythrocytes and SSBGS. Instead, these differences could reflect the heterogeneity of antibody molecules with respect to the size of their specific combining sites (25, 26) . Kabat (25, 26) has demonstrated that antidextran molecules vary considerably in the size of their combining sites, with The term "immune" for agglutinins which cross the placenta, as opposed to "natural" saline agglutinins (8, 27) , is not supported by the present data. All ABO agglutinins appear to be immune responses to antigenic structural groupings resembling those defined by Kabat (10) for human blood group substances.
The nature of the distinction between A, and A2 red cells is also subject to review. Anti-A1 reagents of human, animal or plant origin are highly susceptible to inhibition by SSBGS, and precipitate with SSBGS in common with anti-A (28). The distinction made by these reagents thus appears to be on a quantitative basis: there is more The column chromatographic isolation of isoagglutinins which can cross the placenta appears to be a valuable method for the study of all forms of maternal isoimmunization in relation to erythroblastosis. This method is now being used for its applicability to Rh problems, and the results appear promising, but not identical with the report of Abelson and Rawson (29) .
The column chromatographic method requires at least two days to perform and is not feasible for rapid diagnosis in the newborn period. For prenatal tests, the method appears to be practical. SUMMARY AND CONCLUSION 1. ABO isoagglutinins associated with the bulk of 7S 72-globulins were separated from other serum proteins by anion exchange column chromatography.
2. The ABO isoagglutinin activity of 33 cord blood sera was found to be restricted to 7S 72-globulin-containing fractions.
3. Maternal serum ABO isoagglutinins were encountered chiefly in macroglobulin-containing fractions, but paired specimens of maternal and cord sera obtained at the time of delivery revealed that the 7S 72-globulins as well as the associated isoagglutinins existed in equilibrium on both sides of the placenta.
4. Out of 110 unselected prenatal sera, isoagglutinins, in a titer of at least 1: 2 in acacia, were eluted in 0.02 M phosphate buffer, pH 6.3, in 53 of 73 type 0 mothers, but not in 28 type A and 9 type B women. Anti-A (a) was noted in 51 of these fractions, but anti-B (,8) in only 27. These findings were considered to be consistent with the rarity of ABO erythroblastosis in offspring of mothers not of type 0, and with the excess of erythroblastosis due to anti-A. 5 . When these 53 examples of chromatographically separated isoagglutinins were tested for resistance to inhibition by specific soluble blood group substances (SSBGS) (hog A and horse B), only 5 contained markedly resistant antibodies. Four of these mothers delivered type 0 children, but one mother delivered a type B child who had erythroblastosis and required exchange transfusion therapy. An additional nine mothers in this series also delivered ABO-incompatible newborn, and their 0.02 M fractions contained type-specific isoagglutinins in a titer ranging from 1: 20 to 1: 160, but in each instance these antibodies were readily inhibitable with SSBGS, and clinical erythroblastosis was not observed.
6. Six other women with a history of having had one or more children with severe ABO erythroblastosis, and five unselected donors who had been immunized previously with SSBGS were all found to have such type-specific noninhibitable isoagglutinins.
7. The use of these methods in prenatal tests is implied.
